Navigation Links
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Date:6/1/2009

ur weeks, respectively, achieved clinical remission as measured by the CDAI.

No new or unexpected safety signals were observed in this study. Adverse events were previously reported from the WELCOME study: the most common adverse events were headache, nasopharyngitis and nausea. The incidence of serious adverse events (SAEs) was seven percent and the most frequent SAEs involved gastrointestinal disorders (five percent) and infections and infestations (2 percent).

Additional data from the WELCOME study presented at DDW, includes:

  • Health-related Quality of Life: Cimzia(R) (400 mg) administered at every two or four weeks similarly improved patient-reported health-related quality of life as measured by the Inflammatory Bowel Disease Questionnaire (a validated tool assessing bowel symptoms, systematic symptoms, emotional function and social function) by Week 26. (Abstract #S1058)
  • Efficacy Independent of IFX Dosing: Cimzia(R) (400 mg) was efficacious in rapidly inducing a clinical response in the infliximab-refractory patient population regardless of the previous dosages of infliximab. (Abstract #S1064)

"As we continue to study Cimzia(R)'s potential efficacy, we are pleased to be adding to an impressive body of data that supports the use of Cimzia(R) for a variety of moderate to severe Crohn's disease patients," said David Robinson, vice president and general manager of UCB's Immunology Business Unit.

Recently, UCB announced that Cimzia(R) is now available to Crohn's patients in a pre-filled syringe, developed in partnership with OXO Good Grips(R) for subcutaneous self-administration once every four weeks after initial dosing. Cimzia(R), manufactured by UCB, was approved by the U.S. Food and Drug Administration on April 22, 2008.

About WELCOME

The WELCOME study is a 539 pa
'/>"/>

SOURCE UCB, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
2. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Resverlogix Provides Quarterly Update
7. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. US Oncology Provides Full Service Management of Clinical Trials
10. SemBioSys provides update on insulin program
11. Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and TEL AVIV, Israel , May ... the "Company") (NYSE MKT: NSPR), a leader in embolic protection ... Company,s President and Chief Executive Officer, and Craig ... in the Benchmark Company, LLC One-on-One Investor Conference on Thursday ... Ave., Milwaukee, WI. The ...
(Date:5/24/2013)... 2013 Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients, ... Ph.D., the Company,s Vice President, Biology and ... Corporate Communications, will present an overview of Senomyx,s technology ... Eastern Time (7:25 a.m. Pacific Time) during the Citi ...
(Date:5/24/2013)... This market report summarizes the industry-wide ... out in May 2013. The full report provides ... responses for each question, its segmentation and the ... some interesting differences, particularly between Pharma, Biotech and ... developed to estimate the in house and outsourced ...
(Date:5/24/2013)... 24, 2013 Many factors impact tissues ... or efflux transporters at the blood-tissue barrier. Even when ... unbound fractions in the tissue rather than the total ... challenges is required to guide lead optimization, predict in ... species-dependent variables that may impact the likely human clinical ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2
... Lessons. Legacy.") features,Carnegie-Mellon Professor,s fight against pancreatic cancer and underscores, his call-to-action ... ... debuts on heels of Lustgarten Foundation,s limited online book offer,as seen on ABC ... ...
... 17 Spherix Incorporated,(Nasdaq: SPEX ) announced the ... Brown will be monitoring and overseeing all aspects of ... Naturlose(R) as a,treatment for Type 2 diabetes. The hiring ... with the Contract Research Organization (CRO),take over full control ...
... BioMed Realty Trust, Inc.,(NYSE: BMR ) today ... of common stock at $25.50 per share. The offering ... Gross proceeds from the offering will be,approximately $145.4 million. ... to repay a portion of the outstanding indebtedness under ...
Cached Biology Technology:The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring 'Last Lecturer' Dr. Randy Pausch 2Spherix Hires Key Employees 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 3
(Date:5/24/2013)... one French Quarter neighborhood of New Orleans to determine ... Hurley, PhD, Assistant Professor of Audiology at LSU Health ... LSUHSC doctor of audiology student, recommend that people use ... case study is published online in the current issue ... important part of an audiologist,s practice is aiding patients ...
(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/24/2013)... from around the world today issued a stark warning ... one or two generations, the majority of the 9 ... handicap of severe pressure on fresh water, an absolutely ... This handicap will be self-inflicted and is, we believe, ... underlying problems led by mismanagement and sent a prescription ...
Breaking Biology News(10 mins):Please do try this at home 2A new strategy required in the search for Alzheimer's drugs? 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4
... An investigation of the genes that govern spore formation in ... role in determining which of the microbes sacrifice themselves for ... B. subtilis, a common soil bacteria, is a well-known survivor. ... in colonies or encase itself in a tough, protective spore ...
... -- European breast cancer specialists have taken a ... by bringing together world leaders in breast cancer research ... IMPAKT (IMProving cAre and Knowledge in Translational research). ... May 2009 in Brussels, Belgium, is designed to present ...
... Versions Support Development of Web-based Applications, Live Face ... ... Biometric Identification, VILNIUS, ... high-precision biometric identification,technologies, today announced the availability of two ...
Cached Biology News:Are sacrificial bacteria altruistic or just unlucky? 2Improving care and knowledge in translational research to fight breast cancer 2VeriFinger 6.0 SDK for Fingerprint Recognition and VeriLook 3.2 SDK for Facial Recognition are Now Available 2VeriFinger 6.0 SDK for Fingerprint Recognition and VeriLook 3.2 SDK for Facial Recognition are Now Available 3
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Spaced cover glasses to promote effective hybridization...
prototype Nco I...
... via cardiac puncture from 3 to 4 week ... is then centrifuged and frozen at -70C. The ... at 4C then stored at -70C. DIRECT SALES ... PEL-FREEZ COMPLEMENT, YOU CAN NOW BUY DIRECTLY FROM ...
Biology Products: